GSK and Synta announce STA-4783 collaboration
GSK and Synta announce STA-4783 collaboration
LONDON, UKGlaxoSmithKline and Synta Pharmaceuticals Corp have reached an agreement for the joint development and commercialization of STA-4783 (elesclomol), a first-in-class, small-molecule oxidative stress inducer that is entering phase III development for the treatment of metastatic melanoma (see page 19). The companies will share responsibility for development of STA-4783 in the United States, and GSK will have exclusive responsibility for development outside the US.
Articles in this issue
MT103, BiTE antibody, enters phase II testing for ALL
Sides dig in as ESA policy debate heats up
Ixempra gets ok for resistant breast cancer
ASCO adds Oncotype DX to marker guideline
Dr. Norton hopes to weed 'molecular' tumor garden
Accelerated approval for Tasigna
Oxidative stress inducer ups survival in advanced melanoma
FDA removes partial hold on Telcyta clinical development
Should all HER2+ pts receive adjuvant trastuzumab?
R-CHOP is standard of care for advanced DLBCL patients
FDA oks Velcade for patients with renal dysfunction
Phase II trials planned for oral methylnaltrexone for chronic pain
GSK and Synta announce STA-4783 collaboration
2007: A tumultuous year for erythropoietic-stimulating agents
MB07133 gets orphan drug status
Recent Videos
